Published in J Biol Chem on August 25, 2011
The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science (2012) 2.06
Sampling the conformational space of the catalytic subunit of human γ-secretase. Elife (2015) 1.51
γ-Secretase inhibitors and modulators. Biochim Biophys Acta (2013) 1.32
Development and mechanism of γ-secretase modulators for Alzheimer's disease. Biochemistry (2013) 1.18
Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. J Biol Chem (2011) 0.97
The backbone dynamics of the amyloid precursor protein transmembrane helix provides a rationale for the sequential cleavage mechanism of γ-secretase. J Am Chem Soc (2013) 0.93
Conformational changes induced by the A21G Flemish mutation in the amyloid precursor protein lead to increased Aβ production. Structure (2014) 0.93
FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. J Neurosci (2014) 0.91
Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer's disease early phenotypes. Mol Neurodegener (2014) 0.83
γ-Secretase processing and effects of γ-secretase inhibitors and modulators on long Aβ peptides in cells. J Biol Chem (2013) 0.82
Steroids as γ-secretase modulators. FASEB J (2013) 0.82
Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulators. Biochemistry (2014) 0.81
Independent relationship between amyloid precursor protein (APP) dimerization and γ-secretase processivity. PLoS One (2014) 0.80
Transmembrane Substrate Determinants for γ-Secretase Processing of APP CTFβ. Biochemistry (2016) 0.77
Evidence that enzyme processivity mediates differential Aβ production by PS1 and PS2. Curr Alzheimer Res (2013) 0.77
Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator. Mol Neurodegener (2015) 0.76
Specific Binding of Cholesterol to C99 Domain of Amyloid Precursor Protein Depends Critically on Charge State of Protein. J Phys Chem Lett (2016) 0.75
Aftins increase amyloid-β42, lower amyloid-β38, and do not alter amyloid-β40 extracellular production in vitro: toward a chemical model of Alzheimer's disease? J Alzheimers Dis (2013) 0.75
Zinc and Copper Differentially Modulate Amyloid Precursor Protein Processing by γ-Secretase and Amyloid-β Peptide Production. J Biol Chem (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 14.72
Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature (2005) 11.49
Topogenic signals in integral membrane proteins. Eur J Biochem (1988) 5.16
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 4.92
Amyloid precursor protein trafficking, processing, and function. J Biol Chem (2008) 4.79
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med (2005) 4.00
How proteins adapt to a membrane-water interface. Trends Biochem Sci (2000) 3.76
Substrate-targeting gamma-secretase modulators. Nature (2008) 3.38
Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev (2010) 2.64
GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J (2007) 2.61
gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci (2009) 2.49
Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci (2008) 2.29
The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem (1996) 2.27
Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron (2010) 2.20
Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med (2004) 1.91
Combinatorial alanine-scanning. Curr Opin Chem Biol (2001) 1.82
Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. J Biol Chem (2006) 1.66
Molecular genetics of Alzheimer's disease: an update. Ann Med (2008) 1.62
gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. J Biol Chem (2005) 1.61
Snorkeling of lysine side chains in transmembrane helices: how easy can it get? FEBS Lett (2003) 1.57
Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. EMBO J (2002) 1.57
Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem (2008) 1.54
Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. J Biol Chem (2003) 1.49
Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc Natl Acad Sci U S A (2010) 1.47
Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci U S A (1999) 1.46
Secretion of the Notch-1 Abeta-like peptide during Notch signaling. J Biol Chem (2006) 1.44
Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J (2011) 1.35
Allosteric modulation of PS1/gamma-secretase conformation correlates with amyloid beta(42/40) ratio. PLoS One (2009) 1.34
Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet (2001) 1.33
A two-step procedure for efficient electrotransfer of both high-molecular-weight (greater than 400,000) and low-molecular-weight (less than 20,000) proteins. Anal Biochem (1987) 1.30
Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. J Biol Chem (2004) 1.30
Mutations in APP have independent effects on Abeta and CTFgamma generation. Neurobiol Dis (2004) 1.29
Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R D (2006) 1.25
gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length. J Biol Chem (1999) 1.24
Orientation and dynamics of transmembrane peptides: the power of simple models. Eur Biophys J (2009) 1.18
Three-amino acid spacing of presenilin endoproteolysis suggests a general stepwise cleavage of gamma-secretase-mediated intramembrane proteolysis. J Neurosci (2010) 1.18
Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. J Biol Chem (2007) 1.13
Beta-amyloid precursor protein mutants respond to gamma-secretase modulators. J Biol Chem (2010) 1.12
A novel substrate for analyzing Alzheimer's disease gamma-secretase. FEBS Lett (1999) 1.06
Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. J Biol Chem (2011) 0.97
Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. J Alzheimers Dis (2009) 0.97
Conversion of the LXR-agonist TO-901317--from inverse to normal modulation of gamma-secretase by addition of a carboxylic acid and a lipophilic anchor. Bioorg Med Chem Lett (2007) 0.92
A two decade contribution of molecular cell biology to the centennial of Alzheimer's disease: are we progressing toward therapy? Int Rev Cytol (2006) 0.91
Electrophoretic mobility of Alzheimer's amyloid-beta peptides in urea-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem (2003) 0.83
The triplet of lysine residues (Lys724-Lys725-Lys726) of Alzheimer's amyloid precursor protein plays an important role in membrane anchorage and processing. J Neurochem (1993) 0.79
Medicine. Avoiding unintended toxicity. Science (2009) 0.78
Qualitative and quantitative characterization of the amyloid beta peptide (Abeta) population in biological matrices using an immunoprecipitation-LC/MS assay. J Neurosci Methods (2007) 0.78
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron (2013) 5.91
Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature (2012) 5.47
Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell (2002) 5.15
Amyloid precursor protein trafficking, processing, and function. J Biol Chem (2008) 4.79
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med (2009) 4.11
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med (2005) 4.00
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 3.52
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest (2003) 3.50
Substrate-targeting gamma-secretase modulators. Nature (2008) 3.38
An abundance of small exoplanets around stars with a wide range of metallicities. Nature (2012) 3.25
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol (2005) 2.81
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67
Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell (2002) 2.37
Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem (2003) 2.31
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood (2008) 2.24
Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J (2005) 2.16
Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis (2002) 2.14
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther (2005) 2.02
Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J (2005) 1.98
The amyloid precursor protein: beyond amyloid. Mol Neurodegener (2006) 1.98
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol (2013) 1.95
A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry (2002) 1.93
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci (2011) 1.86
Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest (2007) 1.80
The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J (2002) 1.79
FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci (2004) 1.79
Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia. Nat Neurosci (2009) 1.75
TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. J Immunol (2003) 1.75
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J (2009) 1.73
AMPA receptors regulate transcription of the plasticity-related immediate-early gene Arc. Nat Neurosci (2006) 1.72
Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood (2008) 1.69
Notch signaling is activated by TLR stimulation and regulates macrophage functions. Eur J Immunol (2008) 1.68
Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A (2008) 1.64
Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene (2005) 1.63
BRI2 (ITM2b) inhibits Abeta deposition in vivo. J Neurosci (2008) 1.62
Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. J Biol Chem (2005) 1.61
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener (2011) 1.58
IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol (2010) 1.55
Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol (2014) 1.54
Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem (2008) 1.54
Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J Neurosci (2006) 1.52
Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci (2006) 1.51
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (2013) 1.50
Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. J Biol Chem (2003) 1.49
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci (2007) 1.48
Caspase cleavage of members of the amyloid precursor family of proteins. J Neurochem (2002) 1.46
Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord (2007) 1.44
Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther (2011) 1.43
Alcohol and drug treatment population profile: a comparison of 1998 and 2004 data in New Zealand. N Z Med J (2006) 1.43
Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs. Biochemistry (2006) 1.41
Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem (2003) 1.40
Identification of a novel family of presenilin homologues. Hum Mol Genet (2002) 1.40
Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem (2007) 1.38
Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res (2010) 1.37
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes. Ann Neurol (2003) 1.36
Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J (2006) 1.32
γ-Secretase inhibitors and modulators. Biochim Biophys Acta (2013) 1.32
5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.31
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol (2011) 1.29
C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation. J Neurochem (2005) 1.27
Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation. J Biol Chem (2009) 1.25
Induced dimerization of the amyloid precursor protein leads to decreased amyloid-beta protein production. J Biol Chem (2009) 1.25